197 related articles for article (PubMed ID: 10446945)
1. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group.
Donadio JV; Grande JP; Bergstralh EJ; Dart RA; Larson TS; Spencer DC
J Am Soc Nephrol; 1999 Aug; 10(8):1772-7. PubMed ID: 10446945
[TBL] [Abstract][Full Text] [Related]
2. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group.
Donadio JV; Bergstralh EJ; Offord KP; Spencer DC; Holley KE
N Engl J Med; 1994 Nov; 331(18):1194-9. PubMed ID: 7935657
[TBL] [Abstract][Full Text] [Related]
3. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial.
Praga M; Gutiérrez E; González E; Morales E; Hernández E
J Am Soc Nephrol; 2003 Jun; 14(6):1578-83. PubMed ID: 12761258
[TBL] [Abstract][Full Text] [Related]
4. Clinical and histopathologic associations with impaired renal function in IgA nephropathy. Mayo Nephrology Collaborative Group.
Donadio JV; Bergstralh EJ; Offord KP; Holley KE; Spencer DC
Clin Nephrol; 1994 Feb; 41(2):65-71. PubMed ID: 8004831
[TBL] [Abstract][Full Text] [Related]
5. Short-term effects of fish oil treatment on urinary excretion of high- and low-molecular weight proteins in patients with IgA nephropathy.
Branten AJ; Klasen IS; Wetzels JF
Clin Nephrol; 2002 Oct; 58(4):267-74. PubMed ID: 12400841
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial.
Frisch G; Lin J; Rosenstock J; Markowitz G; D'Agati V; Radhakrishnan J; Preddie D; Crew J; Valeri A; Appel G
Nephrol Dial Transplant; 2005 Oct; 20(10):2139-45. PubMed ID: 16030050
[TBL] [Abstract][Full Text] [Related]
7. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria.
Coppo R; Peruzzi L; Amore A; Piccoli A; Cochat P; Stone R; Kirschstein M; Linné T
J Am Soc Nephrol; 2007 Jun; 18(6):1880-8. PubMed ID: 17513327
[TBL] [Abstract][Full Text] [Related]
8. Treatment of immunoglobulin A nephropathy.
Schiele J; Nowack R; Julian BA; van der Woude FJ
Ann Med Interne (Paris); 1999 Feb; 150(2):127-36. PubMed ID: 10392261
[TBL] [Abstract][Full Text] [Related]
9. Fish oil therapy in IgA nephropathy.
Fung SM; Ferrill MJ; Norton LL
Ann Pharmacother; 1997 Jan; 31(1):112-5. PubMed ID: 8997477
[TBL] [Abstract][Full Text] [Related]
10. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial.
Pozzi C; Andrulli S; Del Vecchio L; Melis P; Fogazzi GB; Altieri P; Ponticelli C; Locatelli F
J Am Soc Nephrol; 2004 Jan; 15(1):157-63. PubMed ID: 14694168
[TBL] [Abstract][Full Text] [Related]
11. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
Liu LJ; Yang YZ; Shi SF; Bao YF; Yang C; Zhu SN; Sui GL; Chen YQ; Lv JC; Zhang H
Am J Kidney Dis; 2019 Jul; 74(1):15-22. PubMed ID: 30922594
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin antagonists and fish oil for treating IgA nephropathy.
Coppo R; Amore A; Peruzzi L; Mancuso D; Camilla R
Contrib Nephrol; 2007; 157():27-36. PubMed ID: 17495434
[TBL] [Abstract][Full Text] [Related]
13. Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy?
Donadio JV; Bergstralh EJ; Bibus DM; Grande JP
Clin J Am Soc Nephrol; 2006 Sep; 1(5):933-9. PubMed ID: 17699310
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial.
Ihle BU; Whitworth JA; Shahinfar S; Cnaan A; Kincaid-Smith PS; Becker GJ
Am J Kidney Dis; 1996 Apr; 27(4):489-95. PubMed ID: 8678058
[TBL] [Abstract][Full Text] [Related]
15. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
Li PK; Leung CB; Chow KM; Cheng YL; Fung SK; Mak SK; Tang AW; Wong TY; Yung CY; Yung JC; Yu AW; Szeto CC;
Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
Manno C; Torres DD; Rossini M; Pesce F; Schena FP
Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
[TBL] [Abstract][Full Text] [Related]
17. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin.
Perico N; Remuzzi A; Sangalli F; Azzollini N; Mister M; Ruggenenti P; Remuzzi G
J Am Soc Nephrol; 1998 Dec; 9(12):2308-17. PubMed ID: 9848785
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
Lv J; Zhang H; Chen Y; Li G; Jiang L; Singh AK; Wang H
Am J Kidney Dis; 2009 Jan; 53(1):26-32. PubMed ID: 18930568
[TBL] [Abstract][Full Text] [Related]
19. [Immunosuppressive therapy in IgA glomerulonephritis with chronic renal failure: case study presentation and literature review].
Pozzi C; Del Vecchio L; Locatelli F
G Ital Nefrol; 2002; 19(5):523-8. PubMed ID: 12439840
[TBL] [Abstract][Full Text] [Related]
20. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
Lv J; Zhang H; Wong MG; Jardine MJ; Hladunewich M; Jha V; Monaghan H; Zhao M; Barbour S; Reich H; Cattran D; Glassock R; Levin A; Wheeler D; Woodward M; Billot L; Chan TM; Liu ZH; Johnson DW; Cass A; Feehally J; Floege J; Remuzzi G; Wu Y; Agarwal R; Wang HY; Perkovic V;
JAMA; 2017 Aug; 318(5):432-442. PubMed ID: 28763548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
